Low dose methods for treating disorders in which TNFalpha activity is detrimental

Details for Australian Patent Application No. 2010206042 (hide)

Owner Abbott Biotechnology Ltd.

Inventors Kamen, Robert; Kaymakcalan, Zehra

Agent Spruson & Ferguson

Pub. Number AU-A-2010206042

Parent 2003301522

Filing date 29 July 2010

Wipo publication date 19 August 2010

International Classifications

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 38/19 (2006.01) Medicinal preparations containing peptides - Cytokines

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 14/715 (2006.01) Peptides having more than 20 amino acids

Event Publications

19 August 2010 Application Open to Public Inspection

  Published as AU-A-2010206042

19 August 2010 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010206043-Guide system for power modules

2010206041-Novel vaccine formulations